Ivermectin Ratiopharm

Ivermectin, the active ingredient in Ivermectin Ratiopharm, is an anthelmintic presented as an oral tablet for oral use. It treats a range of parasitic worm infections and ectoparasitic infestations, including onchocerciasis, strongyloidiasis, scabies, and lymphatic filariasis, in adults and children as prescribed by a healthcare professional.

GNH USA supplies Ivermectin Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, with robust quality‑assurance processes and regulatory compliance across EU and global markets, ensuring consistent product availability and support for healthcare providers.

Ivermectin is an anthelmintic that targets parasitic nematodes and ectoparasites, providing therapeutic benefit in several helminthic and mite‑related diseases. - Onchocerciasis: reduces microfilarial load and prevents disease progression. - Strongyloidiasis: eradicates intestinal Strongyloides stercoralis infection. - Scabies: eliminates Sarcoptes scabiei infestation and relieves itching. - Lymphatic filariasis: clears filarial worms and helps interrupt transmission. - Other helminth infections: treats various nematode infections such as ascariasis and hookworm.

Adverse reactions to Ivermectin are generally mild but can include more serious events in rare cases.

Common Side Effects: - Nausea: mild stomach upset often reported. - Diarrhea: loose stools occurring after dosing. - Dizziness: transient light‑headedness. - Pruritus: skin itching unrelated to parasitic infection. - Fatigue: feeling of tiredness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, swelling, or anaphylaxis. - Neurological signs: seizures, ataxia, or altered consciousness. - Hepatotoxicity: elevated liver enzymes. - Visual disturbances: blurred vision or optic neuritis.

Before prescribing Ivermectin, clinicians should consider several precautionary measures to ensure safe use. - Indication verification: confirm diagnosis of a susceptible parasitic infection. - Age restrictions: use only in patients for whom safety has been established, typically children above a certain weight. - Liver function: assess hepatic impairment as metabolism may be reduced. - Concomitant CNS drugs: avoid co‑administration with medications that lower seizure threshold. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Ivermectin may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers: such as rifampicin, may reduce ivermectin plasma levels. - P‑glycoprotein inhibitors: like verapamil, can increase ivermectin exposure.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for enhanced bleeding risk. - CNS depressants: observe for additive central nervous system effects. - Other antiparasitics: assess for cumulative toxicity.